Scientific Statements on Brain
Cytoprotection in Ischemic Stroke—A Scientific Statement from the Chinese
Stroke Association

doi:10.3969/j.issn.1673-5765.2024.08.012

Abstract

Abstract: Ischemic stroke is one of the serious diseases that cause death and disability. One of the important reasons for the unsatisfactory prognosis of patients with ischemic stroke is the damage to brain tissue resulting from the ischemic cascade reaction. Therefore, active brain cytoprotection therapy is essential for ischemic stroke treatment. In recent years, evidence from many preclinical studies and clinical research has emerged at home and abroad. With the emergence of new therapeutic targets and breakthroughs in treatment approaches, combined with the content of the latest Stroke Treatment Academic Industry Roundtable, this paper makes a scientific statement on the exploration of strategies to bridge the gap of clinical transformation in ischemic stroke, clinical research on brain cytoprotection, and how can exploration contribute to the clinical transformation of more treatment approaches. The objective is to promote the development of preclinical studies and clinical research in brain cytoprotection for ischemic stroke, and further improve the clinical prognosis of patients with ischemic stroke.

Key words: Brain cytoprotection; Ischemic stroke; Scientific statement

摘要： 缺血性卒中是致死致残的重症疾病之一。缺血性卒中患者预后不理想的重要原因之一是缺血级联反应造成的脑组织损伤。因此，积极的脑细胞保护治疗对改善缺血性卒中的预后至关重要。近年来，国内外大量临床前和临床研究证据层出不穷。基于更多新治疗靶点的涌现以及更多治疗方式的突破，结合最新卒中治疗学术产业圆桌会议的内容，本声明对缩小目前缺血性卒中研究临床转化鸿沟的探索、脑细胞保护的临床研究，以及如何有助于实现更多治疗方式的临床转化做一科学声明，旨在推进缺血性卒中脑细胞保护临床前及临床研究的开展，进一步改善缺血性卒中患者的临床预后。

关键词: 脑细胞保护; 缺血性卒中; 科学声明

CLC Number:

LU Dan, CHEN Weiqi, WANG Yaping, DUAN Wanying, GUO Lei, WANG Ling, LIU Liping, XU Anding, WANG Yongjun, Cerebroprotection Academic Roundtable Academic Committee of Chinese Stroke Association .

Scientific Statements on Brain Cytoprotection in Ischemic Stroke—A Scientific Statement from the Chinese Stroke Association [J]. Chinese Journal of Stroke, 2024, 19(8): 938-955.

逯丹, 陈玮琪, 王雅平, 段婉莹, 郭蕾, 王玲, 刘丽萍, 徐安定, 王拥军, 中国卒中学会脑保护圆桌会学术委员会.

缺血性卒中脑细胞保护科学声明——来自中国卒中学会的科学声明 [J]. 中国卒中杂志, 2024, 19(8): 938-955.

References

[1] NIE X M，LENG X Y，MIAO Z R，et al. Clinically ineffective reperfusion after endovascular therapy in acute ischemic stroke[J]. Stroke，2023，54（3）：873-881.

[2] KLEINDORFER D O，TOWFIGHI A，CHATURVEDI S，et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack：a guideline from the American Heart Association/American Stroke Association[J/OL]. Stroke，2021，52（7）：e364-e467[2024-01-01]. https://doi.org/10.1161/STR.
0000000000000375.

[3] XIONG Y Y，WAKHLOO A K，FISHER M. Advances in acute ischemic stroke therapy[J]. Circ Res，2022，130（8）：1230-1251.

[4] Stroke Therapy Academic Industry Roundtable（STAIR）. Recommendations for standards regarding preclinical neuroprotective and restorative drug development[J]. Stroke，1999，30（12）：2752-2758.

[5] WECHSLER L R，ADEOYE O，ALEMSEGED F，et al. Most promising approaches to improve stroke outcomes：the Stroke Treatment Academic Industry Roundtable Ⅻ workshop[J]. Stroke，2023，54（12）：3202-3213.

[6] PARSONS A A，IRVING E A，LEGOS J J，et al. Acute stroke therapy：translating preclinical neuroprotection to therapeutic reality[J]. Curr Opin Investig Drugs，2000，1（4）：452-463.

[7] IADECOLA C. The neurovascular unit coming of age：a journey through neurovascular coupling in health and disease[J]. Neuron，2017，96（1）：17-42.

[8] SAVITZ S I，BARON J C，FISHER M，et al. Stroke Treatment Academic Industry Roundtable Ⅹ：brain cytoprotection therapies in the reperfusion era[J]. Stroke，2019，50（4）：1026-1031.

[9] IADECOLA C，SMITH E E，ANRATHER J，et al. The neurovasculome：key roles in brain health and cognitive impairment：a scientific statement from the American Heart Association/American Stroke Association[J/OL]. Stroke，2023，54（6）：e251-e271[2024-01-01]. https://doi.org/10.1161/STR.0000000000000431.

[10] 刘丽萍，周宏宇，段婉莹，等. 中国脑血管病临床管理指南（第2版）（节选）——第4章缺血性脑血管病临床管理推荐意见[J]. 中国卒中杂志，2023，18（8）：910-933.

LIU L P，ZHOU H Y，DUAN W Y，et al. Chinese Stroke Association guidelines for clinical management of cerebrovascular diseases（second edition）（excerpt）— chapter four clinical management of ischemic cerebrovascular diseases[J]. Chin J Stroke，2023，18（8）：910-933.

[11] XU X M，CHEN M Y，ZHU D Y. Reperfusion and cytoprotective agents are a mutually beneficial pair in ischaemic stroke therapy：an overview of pathophysiology，pharmacological targets and candidate drugs focusing on excitotoxicity and free radical[J/OL]. Stroke Vasc Neurol，2023，svn-2023-002671[2024-01-01].
https://doi.org/10.1136/svn-2023-002671.

[12] HAN B，ZHANG Y，ZHANG Y H，et al. Novel insight into circular RNA HECTD1 in astrocyte activation via autophagy by targeting miR142-TIPARP：implications for cerebral ischemic stroke[J]. Autophagy，2018，14（7）：1164-1184.

[13] BAI Y，ZHANG Y，HAN B，et al. Circular RNA DLGAP4 ameliorates ischemic stroke outcomes by targeting miR-143 to regulate endothelial-mesenchymal transition associated with blood-brain barrier integrity[J]. J Neurosci，2018，38（1）：32-50.

[14] YANG Z G，HUANG C，WEN X Y，et al. Circular RNA circ-FoxO3 attenuates blood-brain barrier damage by inducing autophagy during ischemia/reperfusion[J]. Mol Ther，2022，30（3）：1275-1287.

[15] LI B，XI W，BAI Y，et al. FTO-dependent m6A modification of Plpp3 in circSCMH1-regulated vascular repair and functional recovery following stroke
[J/OL]. Nat Commun，2023，14（1）：489[2024-01-01].
https://doi.org/10.1038/s41467-023-36008-y.

[16] LIU Y F，LI Y F，ZANG J K，et al. CircOGDH is a penumbra biomarker and therapeutic target in acute ischemic stroke[J]. Circ Res，2022，130（6）：907-924.

[17] LIU Y F，ZHANG T Y，ZOU X，et al. Penumbra-targeted circOGDH siRNA-loaded nanoparticles alleviate neuronal apoptosis in focal brain ischaemia[J]. Stroke Vasc Neurol，2024，9（2）：134-144.

[18] HU R Y，LIANG J，DING L，et al. Edaravone dexborneol provides neuroprotective benefits by suppressing NLRP3 inflammasome-induced microglial pyroptosis in experimental ischemic stroke[J/OL]. Int Immunopharmacol，2022，113（Pt A）：109315
[2024-01-01]. https://doi.org/10.1016/j.intimp.2022.109315.

[19] HUANG Y X，ZHANG X J，ZHANG C，et al. Edaravone dexborneol downregulates neutrophil extracellular trap expression and ameliorates blood-brain barrier permeability in acute ischemic stroke[J/OL]. Mediators Inflamm，2022，2022（1）：3855698[2024-01-01].
https://doi.org/10.1155/2022/3855698.

[20] WANG D X，WANG Y T，SHI J F，et al. Edaravone dexborneol alleviates ischemic injury and neuroinflammation by modulating microglial and astrocyte polarization while inhibiting leukocyte infiltration[J/OL]. Int Immunopharmacol，2024，130：111700[2024-01-01]. https://doi.org/10.1016/j. intimp.2024.111700.

[21] ZHANG W，YANG H G，GAO M，et al. Edaravone dexborneol alleviates cerebral ischemic injury via MKP-1-mediated inhibition of MAPKs and activation of Nrf2[J/OL]. Biomed Res Int，2022，2022（1）：4013707
[2024-01-01]. https://doi.org/10.1155/2022/4013707.

[22] FU Y，WANG A X，TANG R H，et al. Sublingual edaravone dexborneol for the treatment of acute ischemic stroke：the TASTE-SL randomized clinical trial[J]. JAMA Neurol，2024，81（4）：319-326.

[23] XU J，WANG A X，MENG X，et al. Edaravone dexborneol versus edaravone alone for the treatment of acute ischemic stroke：a phase Ⅲ，randomized，double-blind，comparative trial[J]. Stroke，2021，52（3）：772-780.

[24] HONG J M，CHOI M H，SOHN S I，et al. Safety and optimal neuroprotection of Neu2000 in acute ischemic stroke with recanalization：study protocol for a randomized，double-blinded，placebo-controlled，phase-Ⅱ trial[J/OL]. Trials，2018，19（1）：375
[2024-01-01]. https://doi.org/10.1186/s13063-018-2746-9.

[25] WU H Y，HUANG Z Q，WANG X，et al. Preclinical evaluation of ZL006-05，a new antistroke drug with fast-onset antidepressant and anxiolytic effects[J]. Stroke Vasc Neurol，2023，8（6）：463-474.

[26] ZHU T，WANG L，WANG L P，et al. Therapeutic targets of neuroprotection and neurorestoration in ischemic stroke：applications for natural compounds from medicinal herbs[J/OL]. Biomed Pharmacother，2022，148：112719[2024-01-01]. https://doi.org/10.1016/j.
biopha.2022.112719.

[27] FANG W R，SHA L，KODITHUWAKKU N D，et al. Attenuated blood-brain barrier dysfunction by XQ-1H following ischemic stroke in hyperlipidemic rats[J]. Mol Neurobiol，2015，52（1）：162-175.

[28] ZHOU X，WANG H Y，WU B，et al. Ginkgolide K attenuates neuronal injury after ischemic stroke by inhibiting mitochondrial fission and GSK-3β-dependent increases in mitochondrial membrane permeability[J]. Oncotarget，2017，8（27）：44682-44693.

[29] YE H B，MA Z F，LIU L，et al. Thrombus inhibition and neuroprotection for ischemic stroke treatment through platelet regulation and ROS scavenging[J/OL]. ChemMedChem，2022，17（24）：e202200317[2024-01-01]. https://doi.org/10.1002/cmdc.202200317.

[30] LI B，ZHANG B K，LI Z Y，et al. Ginkgolide C attenuates cerebral ischemia/reperfusion-induced inflammatory impairments by suppressing CD40/NF-κB pathway
[J/OL]. J Ethnopharmacol，2023，312：116537[2024-01-01].
https://doi.org/10.1016/j.jep.2023.116537.

[31] DONG Y，ZHANG J Y，WANG Y X，et al. Effect of ginkgolide in ischemic stroke patients with large artery atherosclerosis：results from a randomized trial[J]. CNS Neurosci Ther，2021，27（12）：1561-1569.

[32] ZHANG X T，ZHONG W S，MA X D，et al. Ginkgolide with intravenous alteplase thrombolysis in acute ischemic stroke improving neurological function：a multicenter，cluster-randomized trial（GIANT）
[J/OL]. Front Pharmacol，2021，12：792136[2024-01-01].
https://doi.org/10.3389/fphar.2021.792136.

[33] SAVER J L，ALBERS G W，DUNN B，et al. Stroke Therapy Academic Industry Roundtable（STAIR）recommendations for extended window acute stroke therapy trials[J]. Stroke，2009，40（7）：2594-2600.

[34] LYDEN P，BUCHAN A，BOLTZE J，et al. Top priorities for cerebroprotective studies—a paradigm shift：report from STAIR Ⅺ[J]. Stroke，2021，52（9）：3063-3071.

[35] SAVER J L，STARKMAN S，ECKSTEIN M，et al. Prehospital use of magnesium sulfate as neuroprotection in acute stroke[J]. N Engl J Med，2015，372（6）：528-536.

[36] PERCIE DU SERT N，HURST V，AHLUWALIA A，et al. The ARRIVE guidelines 2.0：updated guidelines for reporting animal research[J/OL]. BMC Vet Res，2020，16（1）：242[2024-01-01]. https://doi.org/10.1186/s12917-020-02451-y.

[37] PAUL S，CANDELARIO-JALIL E. Emerging neuroprotective strategies for the treatment of ischemic stroke：an overview of clinical and preclinical studies
[J/OL]. Exp Neurol，2021，335：113518[2024-01-01]. https://doi.org/10.1016/j.expneurol.2020.113518.

[38] BOSETTI F，KOENIG J I，JANIS L S，et al. Organizational update：the NINDS-sponsored stroke preclinical assessment network is moving to its next stage
[J/OL]. Stroke，2021，52（12）：e842-e843[2024-01-01]. https://doi.org/10.1161/STROKEAHA.121.035885.

[39] LYDEN P D，BOSETTI F，DINIZ M A，et al. The stroke preclinical assessment network：rationale，design，feasibility，and stage 1 results[J]. Stroke，2022，53（5）：1802-1812.

[40] HARRIS P A，TAYLOR R，MINOR B L，et al. The REDCap consortium：building an international community of software platform partners[J/OL]. J Biomed Inform，2019，95：103208[2024-01-01].
https://doi.org/10.1016/j.jbi.2019.103208.

[41] LEES K R，KHATRI P，STAIR IX COLLABORATORS. Stroke Treatment Academic Industry Roundtable recommendations for individual data pooling analyses in stroke[J]. Stroke，2016，47（8）：2154-2159.

[42] BOSETTI F，KOENIG J I，AYATA C，et al. Translational stroke research：vision and opportunities[J]. Stroke，2017，48（9）：2632-2637.

[43] VOELKL B，VOGT L，SENA E S，et al. Reproducibility of preclinical animal research improves with heterogeneity of study samples[J/OL]. PLoS Biol，2018，16（2）：e2003693[2024-01-01]. https://doi.org/10.1371/journal.pbio.2003693.

[44] RIJO-FERREIRA F，TAKAHASHI J S. Genomics of circadian rhythms in health and disease[J/OL]. Genome Med，2019，11（1）：82[2024-01-01]. https://doi.org/10.1186/s13073-019-0704-0.

[45] KRINGE L，SENA E S，MOTSCHALL E，et al. Quality and validity of large animal experiments in stroke：a systematic review[J]. J Cereb Blood Flow Metab，2020，40（11）：2152-2164.

[46] ESPOSITO E，LI W L，MANDEVILLE E T，et al. Potential circadian effects on translational failure for neuroprotection[J]. Nature，2020，582（7812）：395-398.

[47] SAVER J L，CHAISINANUNKUL N，CAMPBELL B C V，et al. Standardized nomenclature for modified Rankin scale global disability outcomes：consensus recommendations from Stroke Therapy Academic Industry Roundtable Ⅺ[J]. Stroke，2021，52（9）：3054-3062.

[48] CAMPBELL B C V，LANSBERG M G，BRODERICK J P，et al. Acute Stroke Imaging Research Roadmap Ⅳ：imaging selection and outcomes in acute stroke clinical trials and practice[J]. Stroke，2021，52（8）：2723-2733.

[49] OLIVé-GADEA M，REQUENA M，CAMPOS D，et al. Defining a target population to effectively test a neuroprotective drug[J]. Stroke，2021，52（2）：505-510.

[50] SAMANIEGO E A，BOLTZE J，LYDEN P D，et al. Priorities for advancements in neuroimaging in the diagnostic workup of acute stroke[J]. Stroke，2023，54（12）：3190-3201.

[51] TETTAMANTI M，BERETTA S，PIGNATARO G，et al. Multicentre translational trial of remote ischaemic conditioning in acute ischaemic stroke（TRICS）：protocol of multicentre，parallel group，randomised，preclinical trial in female and male rat and mouse from the Italian Stroke Organization（ISO）basic science network[J/OL]. BMJ Open Sci，2020，4（1）：e100063[2024-01-01]. https://doi.org/10.1136/bmjos-2020-100063.

[52] RIPLEY A J，JEFFERS M S，MCDONALD M W，et al. Neuroprotection by remote ischemic conditioning in rodent models of focal ischemia：a systematic review and meta-analysis[J]. Transl Stroke Res，2021，12（3）：461-473.

[53] DIAZ DIAZ A C，MALONE K，SHEARER J A，et al. Histological，behavioural and flow cytometric datasets relating to acute ischaemic stroke in young，aged and ApoE-/- mice in the presence and absence of immunomodulation with fingolimod[J/OL]. Data Brief，2021，36：107146[2024-01-01]. https://doi.org/10.1016/j.dib.2021.107146.

[54] USUI T，MACLEOD M R，MCCANN S K，et al. Meta-analysis of variation suggests that embracing variability improves both replicability and generalizability in preclinical research[J/OL]. PLoS Biol，2021，19（5）：e3001009[2024-01-01]. https://doi.org/10.1371/journal.pbio.3001009.

[55] MORAIS A，LOCASCIO J J，SANSING L H，et al. Embracing heterogeneity in the multicenter stroke preclinical assessment network（SPAN）trial[J]. Stroke，2023，54（2）：620-631.

[56] MUIR K W，LEES K R，FORD I，et al. Magnesium for acute stroke（intravenous magnesium efficacy in stroke trial）：randomised controlled trial[J]. Lancet，2004，363（9407）：439-445.

[57] DIXON M，APPLETON J P，SCUTT P，et al. Time intervals and distances travelled for prehospital ambulance stroke care：data from the randomised-controlled ambulance-based rapid intervention with glyceryl trinitrate in hypertensive stroke trial-2（RIGHT-2）[J/OL]. BMJ Open，2022，12（11）：e060211[2024-01-01]. https://doi.org/10.1136/bmjopen-2021-060211.

[58] LEES K R，ZIVIN J A，ASHWOOD T，et al. NXY-059 for acute ischemic stroke[J]. N Engl J Med，2006，354（6）：588-600.

[59] SHUAIB A，LEES K R，LYDEN P，et al. NXY-059 for the treatment of acute ischemic stroke[J]. N Engl J Med，2007，357（6）：562-571.

[60] FIDALGO M，RICARDO PIRES J，VISEU I，et al. Edaravone for acute ischemic stroke—systematic review with meta-analysis[J/OL]. Clin Neurol Neurosurg，2022，219：107299[2024-01-01]. https://doi.org/10.1016/j.clineuro.2022.107299.

[61] NI J，YAO M，WANG L H，et al. Human urinary kallidinogenase in acute ischemic stroke：a single-arm，multicenter，phase Ⅳ study（RESK study）[J]. CNS Neurosci Ther，2021，27（12）：1493-1503.

[62] HAUPT M，GERNER S T，BÄHR M，et al. Quest for quality in translational stroke research—a new dawn for neuroprotection？[J/OL]. Int J Mol Sci，2022，23（10）：5381[2024-01-01]. https://doi.org/10.3390/ijms23105381.

[63] WANG C J，GU H Q，DONG Q，et al. Rationale and design of treatment of acute ischaemic stroke with edaravone dexborneol Ⅱ（TASTE-2）：a multicentre randomised controlled trial[J/OL]. Stroke Vasc Neurol，2024：svn-2023-002938[2024-01-01]. https://doi.org/10.1136/svn-2023-002938.

[64] TIAN D C，SHI K B，ZHU Z L，et al. Fingolimod enhances the efficacy of delayed alteplase administration in acute ischemic stroke by promoting anterograde reperfusion and retrograde collateral flow[J]. Ann Neurol，2018，84（5）：717-728.

[65] CHENG Z，GAO J，DING Y，et al. Arterial glyceryl trinitrate in acute ischemic stroke after thrombectomy for neuroprotection（AGAIN）：a pilot randomized controlled trial[J]. Neurotherapeutics，2023，20（6）：1746-1754.

[66] CHAMORRO A，AMARO S，CASTELLANOS M，et al. Safety and efficacy of uric acid in patients with acute stroke（URICO-ICTUS）：a randomised，double-blind phase 2b/3 trial[J]. Lancet Neurol，2014，13（5）：453-460.

[67] PRASAD K，SHARMA A，GARG A，et al. Intravenous autologous bone marrow mononuclear stem cell therapy for ischemic stroke：a multicentric，randomized trial[J]. Stroke，2014，45（12）：3618-3624.

[68] JAILLARD A，HOMMEL M，MOISAN A，et al. Autologous mesenchymal stem cells improve motor recovery in subacute ischemic stroke：a randomized clinical trial[J]. Transl Stroke Res，2020，11（5）：910-923.

[69] CHABRIAT H，BASSETTI C L，MARX U，et al. Safety and efficacy of GABAAα5 antagonist S44819 in patients with ischaemic stroke：a multicentre，double-blind，randomised，placebo-controlled trial[J]. Lancet Neurol，2020，19（3）：226-233.

[70] GONZáLEZ-NIETO D，FERNáNDEZ-SERRA R，PéREZ-RIGUEIRO J，et al. Biomaterials to neuroprotect the stroke brain：a large opportunity for narrow time windows[J/OL]. Cells，2020，9（5）：1074[2024-01-01]. https://doi.org/10.3390/cells9051074.

[71] DáVALOS A，ALVAREZ-SABíN J，CASTILLO J，et al. Citicoline in the treatment of acute ischaemic stroke：an international，randomised，multicentre，placebo-controlled study（ICTUS trial）[J]. Lancet，2012，380（9839）：349-357.

[72] ZHU X Y，MA T T，LI Y，et al. Fingolimod protects against neurovascular unit injury in a rat model of focal cerebral ischemia/reperfusion injury[J]. Neural Regen Res，2023，18（4）：869-874.

[73] LóPEZ-VALDéS H E，CLARKSON A N，AO Y，et al. Memantine enhances recovery from stroke[J]. Stroke，2014，45（7）：2093-2100.

[74] ZHENG H G，WANG Y L，WANG A X，et al. The efficacy and safety of nimodipine in acute ischemic stroke patients with mild cognitive impairment：a double-blind，randomized，placebo-controlled trial[J]. Sci Bull（Beijing），2019，64（2）：101-107.

[75] CHUNG J W，CHANG W H，BANG O Y，et al. Efficacy and safety of intravenous mesenchymal stem cells for ischemic stroke[J/OL]. Neurology，2021，96（7）：e1012-e1023[2024-01-01]. https://doi.org/10.1212/WNL.0000000000011440.

[76] ZHONG J，LI R W，WANG J，et al. Neuroprotection by cattle encephalon glycoside and ignotin beyond the time window of thrombolysis in ischemic stroke[J]. Neural Regen Res，2021，16（2）：312-318.

[77] LI S Y，JIANG D W，EHLERDING E B，et al. Intrathecal administration of nanoclusters for protecting neurons against oxidative stress in cerebral ischemia/reperfusion injury[J]. ACS Nano，2019，13（11）：13382-13389.

[78] KALLADKA D，SINDEN J，POLLOCK K，et al. Human neural stem cells in patients with chronic ischaemic stroke（PISCES）：a phase 1，first-in-man study[J]. Lancet，2016，388（10046）：787-796.

[79] MENG R，DING Y C，ASMARO K，et al. Ischemic conditioning is safe and effective for octo- and nonagenarians in stroke prevention and treatment[J]. Neurotherapeutics，2015，12（3）：667-677.

[80] ZHOU D，DING J Y，YA J Y，et al. Efficacy of remote ischemic conditioning on improving WMHs and cognition in very elderly patients with intracranial atherosclerotic stenosis[J]. Aging（Albany NY），2019，11（2）：634-648.

[81] HOU C B，LAN J，LIN Y N，et al. Chronic remote ischaemic conditioning in patients with symptomatic intracranial atherosclerotic stenosis（the RICA trial）：a multicentre，randomised，double-blind sham-controlled trial in China[J]. Lancet Neurol，2022，21（12）：1089-1098.

[82] ENGLAND T J，HEDSTROM A，O’SULLIVAN S，et al. RECAST（remote ischemic conditioning after stroke trial）：a pilot randomized placebo controlled phase Ⅱ trial in acute ischemic stroke[J]. Stroke，2017，48（5）：1412-1415.

[83] ENGLAND T J，HEDSTROM A，O’SULLIVAN S E，et al. Remote ischemic conditioning after stroke trial 2：a phase Ⅱb randomized controlled trial in hyperacute stroke[J/OL]. J Am Heart Assoc，2019，8（23）：e013572[2024-01-01]. https://doi.org/10.1161/JAHA.119.013572.

[84] CHEN H S，CUI Y，LI X Q，et al. Effect of remote ischemic conditioning vs. usual care on neurologic function in patients with acute moderate ischemic stroke：the RICAMIS randomized clinical trial[J]. JAMA，2022，328（7）：627-636.

[85] ZHAO W B，CHE R W，LI S J，et al. Remote ischemic conditioning for acute stroke patients treated with thrombectomy[J]. Ann Clin Transl Neurol，2018，5（7）：850-856.

[86] HOUGAARD K D，HJORT N，ZEIDLER D，et al. Remote ischemic perconditioning as an adjunct therapy to thrombolysis in patients with acute ischemic stroke：a randomized trial[J]. Stroke，2014，45（1）：159-167.

[87] CHE R W，ZHAO W B，MA Q F，et al. rt-PA with remote ischemic postconditioning for acute ischemic stroke[J]. Ann Clin Transl Neurol，2019，6（2）：364-372.

[88] AN J Q，CHENG Y W，GUO Y C，et al. Safety and efficacy of remote ischemic postconditioning after thrombolysis in patients with stroke[J/OL]. Neurology，2020，95（24）：e3355-e3363[2024-01-01]. https://doi.org/10.1212/WNL.0000000000010884.

[89] WANG Y，MENG R，SONG H Q，et al. Remote ischemic conditioning may improve outcomes of patients with cerebral small-vessel disease[J]. Stroke，2017，48（11）：3064-3072.

[90] MI T M，YU F，JI X M，et al. The interventional effect of remote ischemic preconditioning on cerebral small vessel disease：a pilot randomized clinical trial[J]. Eur Neurol，2016，76（1/2）：28-34.

[91] SU Y Y，FAN L L，ZHANG Y Z，et al. Improved neurological outcome with mild hypothermia in surviving patients with massive cerebral hemispheric infarction[J]. Stroke，2016，47（2）：457-463.

[92] PIIRONEN K，TIAINEN M，MUSTANOJA S，et al. Mild hypothermia after intravenous thrombolysis in patients with acute stroke：a randomized controlled trial[J]. Stroke，2014，45（2）：486-491.

[93] HEMMEN T M，RAMAN R，GULUMA K Z，et al. Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke（ICTuS-L）：final results[J]. Stroke，2010，41（10）：2265-2270.

[94] LYDEN P，HEMMEN T，GROTTA J，et al. Results of the ICTuS 2 trial（intravascular cooling in the treatment of stroke 2）[J]. Stroke，2016，47（12）：2888-2895.

[95] HORN C M，SUN C H J，NOGUEIRA R G，et al. Endovascular reperfusion and cooling in cerebral acute ischemia（ReCCLAIMI）[J]. J Neurointerv Surg，2014，6（2）：91-95.

[96] HONG J M，LEE J S，SONG H J，et al. Therapeutic hypothermia after recanalization in patients with acute ischemic stroke[J]. Stroke，2014，45（1）：134-140.

[97] CHENG Z，DING Y C，RAJAH G B，et al. Vertebrobasilar artery cooling infusion in acute ischemic stroke for posterior circulation following thrombectomy：rationale，design and protocol for a prospective randomized controlled trial[J/OL]. Front Neurosci，2023，17：1149767[2024-01-01]. https://doi.org/10.3389/fnins.2023.1149767.

[98] APPLEBAUM R M，KASLIWAL R，TUNICK P A，et al. Sequential external counterpulsation increases cerebral and renal blood flow[J]. Am Heart J，1997，133（6）：611-615.

[99] HAN J H，LEUNG T W，LAM W W，et al. Preliminary findings of external counterpulsation for ischemic stroke patient with large artery occlusive disease[J]. Stroke，2008，39（4）：1340-1343.

[100] XIONG L，LIN W H，HAN J H，et al. Enhancing cerebral perfusion with external counterpulsation after ischaemic stroke：how long does it last？[J]. J Neurol Neurosurg Psychiatry，2016，87（5）：531-536.

[101] LIN W H，HAN J H，CHEN X Y，et al. Predictors of good functional outcome in counterpulsation-treated recent ischaemic stroke patients[J/OL]. BMJ Open，2013，3（6）：e002932[2024-01-01]. https://doi.org/10.1136/bmjopen-2013-002932.

[102] LIN W H，XIONG L，HAN J H，et al. Increasing pressure of external counterpulsation augments blood pressure but not cerebral blood flow velocity in ischemic stroke[J]. J Clin Neurosci，2014，21（7）：1148-1152.

[103] TIAN G，XIONG L，LIN W H，et al. External counterpulsation reduces beat-to-beat blood pressure variability when augmenting blood pressure and cerebral blood flow in ischemic stroke[J]. J Clin Neurol，2016，12（3）：308-315.

[104] XIONG L，TIAN G，WANG L，et al. External counterpulsation increases beat-to-beat heart rate variability in patients with ischemic stroke[J]. J Stroke Cerebrovasc Dis，2017，26（7）：1487-1492.

[105] HAMMER M D，SCHWAMM L，STARKMAN S，et al. Safety and feasibility of NeuroFlo use in eight-to
24-hour ischemic stroke patients[J]. Int J Stroke，2012，7（8）：655-661.

[106] SHUAIB A，BORNSTEIN N M，DIENER H C，et al. Partial aortic occlusion for cerebral perfusion augmentation：safety and efficacy of NeuroFlo in acute ischemic stroke trial[J]. Stroke，2011，42（6）：1680-1690.

[107] LEVI H，SCHOKNECHT K，PRAGER O，et al. Stimulation of the sphenopalatine ganglion induces reperfusion and blood-brain barrier protection in the photothrombotic stroke model[J/OL]. PloS One，2012，7（6）：e39636[2024-01-01]. https://doi.org/10.1371/journal.pone.0039636.

[108] BORNSTEIN N M，SAVER J L，DIENER H C，et al. Sphenopalatine ganglion stimulation to augment cerebral blood flow：a randomized，sham-controlled trial[J]. Stroke，2019，50（8）：2108-2117.

[109] BORNSTEIN N M，SAVER J L，DIENER H C，et al. An injectable implant to stimulate the sphenopalatine ganglion for treatment of acute ischaemic stroke up to 24 h from onset（ImpACT-24B）：an international，randomised，double-blind，sham-controlled，pivotal trial[J]. Lancet，2019，394（10194）：219-229.

Scientific Statements on Brain Cytoprotection in Ischemic Stroke—A Scientific Statement from the Chinese Stroke Association

缺血性卒中脑细胞保护科学声明——来自中国卒中学会的科学声明

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	WU Songdi. Focusing on Retinal Angiography and Analysis to Enhance the Comprehensive Understanding of Neurological Diseases [J]. Chinese Journal of Stroke, 2024, 19(11): 1239-1245.
[2]	Neuro-Ophthalmology Society, Chinese Research Hospital Association, Neuro-Ophthalmology Society, Shaanxi Research Hospital Association. Expert Consensus on Clinical Diagnosis and Treatment of Central Retinal Artery Occlusion in China [J]. Chinese Journal of Stroke, 2024, 19(11): 1247-1267.
[3]	HUO Yan, LIN Xuemei, LIU Zhongzhong, RAO Lanping, SONG Chensheng, LIU Pei, LU Qingli, WANG Jing, WU Songdi. Clinical Characteristics of Patients with Transsynaptic Retrograde Degeneration of Optic Neuropathy Secondary to Lateral Geniculate Body and Posterior Central Visual Pathway Injury [J]. Chinese Journal of Stroke, 2024, 19(11): 1268-1276.
[4]	ZHANG Mi, LIN Xuemei, LIU Pei, LIU Zhongzhong, LU Qingli, LIU Guozheng, LI Yunfei, RAO Lanping, SONG Chensheng, LI Guo, WU Fanyan, CAO Shundao, SUN Chao, HUO Yan, WANG Yan, LIU Yan, WANG Ning, WU Songdi. Study on the Correlation between Internal Carotid Artery Stenosis and Microvascular Characteristics in Macular Lutea by Optical Coherence Tomography Angiography [J]. Chinese Journal of Stroke, 2024, 19(11): 1277-1287.
[5]	YANG Zijian, FANG Wei, ZHAO Zhenwei, ZHANG Tao, LUO Guoqiang, XING Zifei, LIU Haitao, GUO Xing, DENG Jianping. Safety and Efficacy of Different Approaches for the Interventional Therapy of Cavernous Sinus Dural Arteriovenous Fistula [J]. Chinese Journal of Stroke, 2024, 19(11): 1288-1295.
[6]	ZHAO Mengqiu, KUANG Shenyi, ZHANG Shufan, HAN Xiang, YANG Shilin. A Case Report of Central Retinal Artery Occlusion Caused by Internal Carotid Artery Dissection [J]. Chinese Journal of Stroke, 2024, 19(11): 1296-1300.
[7]	LU Qingli, LIU Pei, SUN Chao, SHI Yaling, LIN Xuemei, WU Songdi. A Case Report of Hypertensive Retinopathy Combined with Posterior Reversible Encephalopathy Syndrome [J]. Chinese Journal of Stroke, 2024, 19(11): 1301-1305.
[8]	LU Qingli, WU Songdi. Anatomical Overview of Blood Supply in Visual Pathway [J]. Chinese Journal of Stroke, 2024, 19(11): 1306-1312.
[9]	XIN Na, LIN Lin, BAI Bo, TIAN Zhaozeng, JIANG Jialin, WANG Tao. Research and Application of Clinical Decision Support System for Acute Cerebral Infarction Diagnosis Coding [J]. Chinese Journal of Stroke, 2024, 19(11): 1313-1320.
[10]	WANG Lu, ZHANG Shibin, LYU Xue, YANG Zhanjun, JIA Jianxin, WU Li’e. Neuroprotective Effect and Mechanism of Glycosides of Cistanche on Cerebral Ischemia-Reperfusion Injury in Rats Based on PI3K-Akt Signaling Pathway [J]. Chinese Journal of Stroke, 2024, 19(11): 1321-1332.
[11]	Chinese Interventional Neuroradiology Society of Chinese Stroke Association. Chinese Expert Consensus on the Management of Medium Vessel Occlusion in Acute Ischemic Stroke 2024 [J]. Chinese Journal of Stroke, 2024, 19(11): 1333-1358.
[12]	YANG Caixia, YI Haibo, QI Lu, HU Qiongdan, SUN Ye, LI Dongmei, MA Keke, LI Yapeng, XU Yuming, GUO Yuanli. Construction of Quality Evaluation Index System for Brain and Heart Health Managers Based on the Structure-Process-Outcome Three-Dimensional Quality Model [J]. Chinese Journal of Stroke, 2024, 19(11): 1359-1367.
[13]	XIE Yaoyi, HUANG Yanju, FAN Min, CEN Huatao, LI Yanli, LU Miaozhi, LU Boan, WEI Rangfang, WU Zhiwu. Study on the Clinical Efficacy of Antiplatelet Therapy Guided by CYP2C19 Gene Detection in Ischemic Stroke Patients of Different Ethnic Groups [J]. Chinese Journal of Stroke, 2024, 19(10): 1119-1124.
[14]	HOU Yuting, LI Tong. A Case Report of Dual Antiplatelet Therapy for Acute Basilar Artery Occlusion Based on Rapid CYP2C19 Gene Detection [J]. Chinese Journal of Stroke, 2024, 19(10): 1125-1130.
[15]	ZHANG Taihui, REN Hong. A Case Report of Dual Antiplatelet Therapy for Severe Stenosis of the Internal Carotid Artery Based on Rapid CYP2C19 Gene Detection [J]. Chinese Journal of Stroke, 2024, 19(10): 1131-1134.